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a b s t r a c t
Neurodegeneration with brain iron accumulation (NBIA) is a group of genetic disorders with
a progressive extrapyramidal syndrome and excessive iron deposition in the brain, particu-
larly in the globus pallidus and substantia nigra. We present the case of a 31-year-old woman
with mitochondrial protein associated neurodegeneration (MPAN). MPAN is a new identiﬁed
subtype of NBIA, caused by mutations in C19orf12 gene. The typical features are speech and
gait disturbances, dystonia, parkinsonism and pyramidal signs. Common are psychiatric
symptoms such as impulsive or compulsive behavior, depression and emotional lability. In
almost all cases, the optic atrophy has been noted and about 50% of cases have had a motor
axonal neuropathy. In the MRI on T2- and T2*-weighted images, there are hypointense
lesions in the globus palidus and substantia nigra corresponding to iron accumulation.
# 2014 Polish Neurological Society. Published by Elsevier Urban & Partner Sp. z o.o. All
rights reserved.
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Neurodegeneration with brain iron accumulation (NBIA) is a
group of genetic disorders with a progressive extrapyramidal
syndrome and excessive iron deposition in the brain,
particularly in the globus pallidus and substantia nigra [1,2].
Mitochondrial protein associated neurodegeneration (MPAN)
is a new identiﬁed subtype of NBIA, caused by mutations in
C19orf12 gene, described primarily in Polish cohort.
2. Case report
We present the case of a 31-year-old woman, a second child of
unrelated parents with no family history of neurological* Corresponding author at: 2nd Department of Neurology, Institute of Ps
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http://dx.doi.org/10.1016/j.pjnns.2013.09.002diseases. She developed ﬁrst symptoms, including occasional
falls, gait impairment and incoordination at the age of 15. Over
the following years, concentration disturbances, problems
with learning, dysarthria and abnormal involuntary move-
ments have developed. She has been admitted several times to
psychiatric clinics with diagnosis of paranoid schizophrenia.
She is still treated with clozapine and olanzapine.
On admission to our department, the contact was impaired
because of severe dysarthria and often freezing episodes. The
neurological examination revealed: swallowing disturbances,
torticollis and involuntary up and down head movements of
the ‘‘yes–yes’’ type, orofacial dystonia with movements of
forehead and eyebrows, chorea in the upper limbs, spastic
tetraparesis with hyperreﬂexia and Babiński sign, talipes
varus, wide-based gait, only with assistance, and sensory loss
in the lower limbs.ychiatry and Neurology, 9 Sobieskiego St., 02-957 Warsaw, Poland.
blished by Elsevier Urban & Partner Sp. z o.o. All rights reserved.
Fig. 1 – MRI of brain of 31-year-old patient with MPAN; T2 weighted images: (A) symmetric, hypointense lesions in the globus
pallidus and (B) substantia nigra bilateral; T2* – weighted images: (C) symmetric, hypointense lesions in the globus pallidus
and (D) substantia nigra bilateral corresponds to the excess iron accumulation. Lesions pointed with arrows.
Fig. 2 – Transcranial sonography of 31-year-old patient with MPAN (A, B) hyperechogenicity of globus pallidus bilateral (red
arrows); anterior horns of the lateral cerebral ventricles (yellow points) and third ventricle (yellow arrows), and (C, D) normal
substantia nigra bilateral. (For interpretation of the references to color in this figure legend, the reader is referred to the web
version of the article.)
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weighted and T2* images has shown low signal intensity in
the lenticular nucleus, especially in the part of lenticular
nucleus in globus pallidus and substantia nigra bilaterally
(Fig. 1). Transcranial sonography (Vivid 7; GE, Wisconsin, USA;
substantia nigra echogenic sizes 0.25 cm2 deﬁned as
hyperechogenic and 20 cm2 as normal) has revealed
hyperechogenicity of lenticular nucleus, and no changes in
substantia nigra bilaterally (Fig. 2). In the laboratory tests,
plasma level of iron, ceruloplasmin, ferritin and transferrin
have been normal. Blood smear has revealed rare acantho-
cytes. Ophthalmological investigation did not show retinop-
athy or optic atrophy. The electromyography has revealed
axonal neuropathy.
Because of clinical and radiological suggestion of iron
deposition, the molecular analyses was done in the Institute of
Human Genetics in Munchen was kindly done and revealed
heterozygous mutation in C19orf12 gene: c.32C > T het p.T11M
+ c.204–214del11bp het p.G69RfsX10 allowing the diagnosis of
NBIA – MPAN.
3. Discussion
Genetic analysis of presented case revealed MPAN – a new
form of NBIA. The most common NBIA is the pantothenate
kinase-associated neurodegeneration (PKAN). PKAN is caused
by a mutation in the PANK2 on chromosome 20p13 and
accounts for about 50–70% of all NBIA [3]. PKAN is character-
ized by rapid progression of extrapyramidal symptoms,
mainly dystonia in children or severe speech and neuropsy-
chiatric disturbances in adults [4–7]. Two types of PKAN have
been described: typical PKAN, with average age of onset about
3–4 years old and late-onset/atypical PKAN, with mean age of
onset 13–14 years old [3,4]. In cases of typical PKAN, on T2-
weighted images hypointense signal in globus pallidus and
substantia nigra is present, often with the characteristic ‘‘eye
of the tiger sign’’ [6–8]. It is a ring of marked hypointensity
involving the globus pallidus corresponding to the excess iron
accumulation with the central high signal intensity. In some
cases, especially in late-onset PKAN, there are hypointense
lesions in the globus pallidus and substantia nigra without
‘‘the eye of the tiger sign’’ on T2-weighted images [9]. In our
case, before receiving molecular diagnosis the atypical type of
PKAN has been suspected, because of age of onset, mild course
of the disease, chorea, rigidity, palipalia, dysarthria and
psychiatric disturbances which are characteristic for this type
of NBIA [1,4].
MPAN is a new autosomal recessive inherited subtype of
NBIA identiﬁed in 2009 in a Polish cohort [10] in 23 patients
with NBIA, and recently in other cohorts [11,12]. It is caused by
mutation in the orphan gene C19orf12 that encodes a protein
expressed in mitochondria. The role of this protein has not
been fully understood, but probably it plays a role in free fatty
acids synthesis and in valine, leucine and isoleucine biochem-
ical pathways [1,13]. Coenzyme A (CoA), the product of PANK2
gene, has also taken part in these biochemical changes. It
could explain similarity with PKAN [3,4].
The clinical progress in MPAN is similar to PKAN, but the
age of onset is later and the expression of symptoms is milder[3]. Most of the patients have extrapyramidal symptoms such
as generalized or/and oromandibular dystonia and parkin-
sonism. Relatively frequent pyramidal signs including spas-
tic paralysis, hyperreﬂexia and Babinski sign are present.
The loss of independent ambulation occurs at the mean age
of 21 [10]. Psychiatric impairments such as impulsive or
compulsive behavior, depression and emotional liability are
common [10]. In almost all cases, the optic atrophy has been
noted. Nearly 50% of cases have had a motor axonal
neuropathy [10]. In the MRI, on T2-weighted images there
is hypointense lesions in the globus pallidus and substantia
nigra bilaterally without central hyperintensity characteris-
tic for ‘‘the eye of the tiger sign’’, that is observed in PKAN
patients [10,13]. Hypointensity corresponds to the excess iron
accumulation.
There are some differences in presented case compared to
the typical course of the disease. Although the age of onset,
and MR picture in our patient are typical, chorea movements in
the upper limbs present in our patient have not been described
in MPAN so far. The optic atrophy is typical, and it has not been
noted in this case.
We also have found rare acanthocytes in the blood smear,
which were described for PKAN and but not for MPAN patients.
We did not ﬁnd substantia nigra hyperechogenicity in
transcranial sonography, but lenticular nucleus hyperecho-
genicity, although MR showed changes in both lenticular
nucleus and substantia nigra. As it is the only one case
presented it needs further observation.
There is no speciﬁc treatment of NBIA until now [3,5,14].
Results of a phase II pilot trial with deferiprone in PKAN has
been published recently, but failed to show clinical efﬁciency
[15]. L-dopa, bromocriptine and trihexyphenidyl are used in
dystonia and rigidity. Botulinum toxin injections and oral or
continuous intrathecal baclofen can be helpful. Chlorproma-
zine, diazepam and clonazepam can be effective in anxiety,
agitation, hyperkinesis and sleep disorders. Deep brain
stimulation is also an option, especially for extreme dystonia
and spasticity, but it gives short-term relief [6,7]. Application of
high dose of pantothenate (1–3 g/24 h) has not been successful
[3,5].
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